Expert Interview
A look at the Phase 1 data from Wave Life Sciences' INLIGHT trial evaluating WVE-007, an investigational INHBE-targeting siRNA therapy, in patients with obesity and type 2 diabetes.
Ticker(s): WVEInstitution: University of Pittsburgh
- Director of Endocrinology and Metabolism Clinical Research Core and Translational Research Center at UPMC.
- Treats 800- 900 obese patients per year who are at risk for major adverse cardiac events.
- Clinical interests are in the areas of diabetes and general endocrinology; Research interests in the etiology and treatment of insulin resistance in humans, medications that improve insulin resistance and beta cell function, and is currently investigating the pathogenesis of pancreatitis-related diabetes to identify new possibilities of prevention and treatment.
How are you currently managing patients with obesity and type 2 diabetes, and what unmet needs remain with existing pharmacologic options?
Added By: sara_adminWhat is your interpretation of the interim Phase 1 INLIGHT data for WVE-007, particularly the observed reductions in visceral fat and preservation of lean mass?
Added By: sara_adminWhich patient populations (e.g., degree of obesity, metabolic profile, comorbidities) do you believe may benefit most from a therapy like WVE-007?
Added By: sara_adminAre You Interested In These Questions?
Slingshot Insights Explained
- Call Date
- Apr 07, 2026
- Call Time
- 11:00 AM EDT
Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.
Reason
*Slingshot Insights provides access to information, not investment advice. We work to support you and facilitate access to experts; however we are not responsible for monitoring calls for the disclosure of MNPI. You should obtain financial, legal and tax advice from your qualified and licensed advisers before deciding to invest in any security.
